Nobody doubts that the Kennedy Trust for Rheumatology Research has made important contributions to the treatment of arthritis. But the London-based research center overreached by demanding more patent royalties from drugmaker and longtime licensee AbbVie Inc. (formerly Abbott Laboratories Inc.), an appeals court ruled Thursday.
In a 28-page ruling, the U.S. Court of Appeals for the Federal Circuit affirmed a decision invalidating one of the Kennedy Trust’s patents on the blockbuster arthritis drug Humira, which is sold by AbbVie. The institute had hoped to use the patent to wring royalties out of AbbVie until 2018.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
